PhRMA

08/11/2025

America’s smart IP policies have incentivized and delivered innovation for patients, but PBMs are creating barriers to accessibility.

A new study shows a troubling pattern: each year the nation’s three largest PBMs have excluded an average of 27% more medicines from many commercial health plans since 2014. This includes an increasing number of generics and biosimilars intended to drive patient savings.

It’s time to increase transparency and hold PBMs accountable.

08/08/2025

A new report shows that as more tax-exempt hospitals exploit the 340B program as a profit center, it increases costs for state and federal taxpayers due to lost Medicaid rebates. In 2024 alone, 340B cost taxpayers and Medicaid an estimated $6.5 billion.

That’s money that could have lowered costs for patients or eased pressure on state budgets. Instead, it’s a hidden tax on patients, taxpayers, and employers—with little benefit for the people the program was meant to serve.

https://phrma.org/blog/the-hidden-cost-of-340b-a-multi-billion-dollar-burden-on-taxpayers-and-medicaid

08/05/2025

The U.S. leads the world in biopharmaceutical innovation—driven by bold investments in R&D and the scientists turning discovery into real-world impact.

To stay competitive and continue breaking new ground in medicine, we must invest in the next generation of talent.

Hear from Nicole Harriott of Neurocrine Biosciences on why nurturing young scientists is critical to America’s leadership in life sciences.

08/04/2025

Every American should have the option to protect themselves and their family with vaccines that are available and accessible. And while vaccines are different by design, they are united in purpose: every vaccine is made to protect Americans.

To kick off National Immunization Awareness Month, PhRMA’s Chief Medical Officer, Mike Ybarra, breaks down how vaccines work, why they matter, and how American innovation helps us stay ahead.

Explore the global impact of American innovation in vaccines at innovation.org/vaccines.

07/30/2025

The New York Times piece, “Health Insurers Are Denying More Drug Claims, Data Shows” details a 25% increase in denials for prescription drug coverage from 2016 to 2023.

A new paper from IQVIA digs into how often patients are being denied and what it takes to fill a new prescription, if at all.

🔗 https://phrma.org/blog/new-study-pbms-and-commercial-insurers-are-quietly-blocking-prescription-access

Prescription drug denials by private insurers in the U.S. jumped 25% from 2016 to 2023, according to a new analysis of more than four billion claims, a practice that has contributed to rising public outrage about the country’s private health insurance system. https://nyti.ms/4m74D93

07/29/2025

💡 New data shows how strong IP protections fuel U.S. innovation and power the biopharmaceutical sector, resulting in:

- 5M jobs
- 1,500+ production facilities in the U.S.
- Innovative treatments and cures

Watch the video + read more: https://phrma.org/blog/new-report-how-intellectual-property-drives-u-s-innovation-and-biopharma-s-impact

07/28/2025

AstraZeneca’s new facility in Rockville, Maryland will boost the local economy, create high-skilled jobs and develop new cancer treatments. Learn more about AstraZeneca’s state-of-the-art cell therapy manufacturing facility and their commitment to investing in American communities: innovation.org

07/28/2025

Amgen’s investment in Central Ohio highlights our industry’s commitment to fostering local talent, supporting economic growth and developing critical medicines. Learn more about Amgen’s innovation and manufacturing achievements across America: innovation.org

07/25/2025

If we want to lower drug costs, we have to fix the policies driving them up. It’s time to rein in PBMs, fix the 340B hospital markup program and end foreign free riding—so we can build a system that works for patients.

07/22/2025

We’re committed to advancing America’s health, economy and global leadership by expanding our manufacturing and research investments across the country. Our centralized hub — Innovation.org — showcases our industry’s efforts toward building a healthier America.

07/21/2025

In the U.S., Pharmacy Benefit Managers (PBMs) charge fees and rebates on medicines that can exceed the total price of that same medicine overseas by as much as 900%. American patients pay more because PBMs use medicines as profit centers.

It’s time to rein in PBMs and lower costs for patients.

https://phrma.org/policy-issues/pbms-middlemen